Pulmonary function in children treated for rhabdomyosarcoma

Area of Science:

• Pediatric Oncology
• Pulmonology
• Toxicology

Background:

• Rhabdomyosarcoma treatment has improved survival but can lead to lung damage.
• Bleomycin, a chemotherapy agent, is known for its potential pulmonary toxicity.
• Assessing pulmonary function in treated patients is crucial due to potential long-term effects.

Purpose of the Study:

• To evaluate pulmonary function in patients treated for rhabdomyosarcoma, particularly those who received bleomycin.
• To identify potential pulmonary dysfunction and risk factors associated with rhabdomyosarcoma therapy.

Main Methods:

• Pulmonary function tests (PFTs) were administered to 17 patients treated for rhabdomyosarcoma.
• Key PFT parameters assessed included total lung capacity (TLC) and carbon monoxide diffusing capacity (DLCO).
• Forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio and FEF25-75 were analyzed, with comparisons based on age at diagnosis.

Main Results:

• 87% of patients exhibited restrictive ventilatory impairment (low TLC).
• 70% showed reduced carbon monoxide diffusing capacity (low DLCO).
• Patients diagnosed over 8 years old had significantly lower FEV1/FVC ratios and FEF25-75 compared to younger patients.

Conclusions:

• Rhabdomyosarcoma survivors treated with chemotherapy, including bleomycin, have a high incidence of restrictive lung abnormalities.
• Age at diagnosis appears to influence the severity of certain pulmonary function deficits.
• Pre- and post-treatment pulmonary function testing is recommended for monitoring lung health in these patients.